Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease

Journal of Investigative Surgery

Volumn 29, Issue 5, 2016, Pages 266-274

  von Loeffelholz, C ^a,b,c   Horn, P ^b,c   Birkenfeld, A L ^d   Claus, R A ^b,c   Metzing, B U ^b,c   Docke S ^a   Jahreis, G ^b   Heller, R ^b,c   Hoppe, S ^e   Stockmann, M ^e   Lock, J F ^f   Rieger, A ^e   Weickert, M O ^g   Settmacher, U ^b   Rauchfuss F ^b   Pfeiffer, A F H ^a,e   Bauer, M ^b,c   Sponholz, C ^c  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Fetuin A; hepatokine; insulin resistance; liver failure; NAFLD; NAFLD screening

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; FAT; FETUIN A; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; TRIACYLGLYCEROL; AHSG PROTEIN, HUMAN; BIOLOGICAL MARKER;

ABDOMINAL SURGERY; ACUTE LIVER FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEPATIC INSULIN RESISTANCE INDEX; HEPATOBILIARY PARAMETERS; HISTOPATHOLOGY; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LIPID LIVER LEVEL; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER SURGERY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; GENETICS; LIPID METABOLISM; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PREOPERATIVE PERIOD;

ALPHA-2-HS-GLYCOPROTEIN; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIPID METABOLISM; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREOPERATIVE PERIOD; RNA, MESSENGER;

EID: 84961215689     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2016.1149640     Document Type: Article

References (37)

1. M.M.Finucane, G.A.Stevens, M.J.Cowan, National, regional, and global trends in body-mass index since 1980:systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011;12:557-567.
2. S.M.Abd El-Kader, E.M.El-Den Ashmawy. Non-alcoholic fatty liver disease:The diagnosis and management. World J Hepatol. 2015;28:846–58.
3. A.Gastaldelli, K.Cusi, M.Pettiti, Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and vtype 2 diabetic subjects. Gastroenterology 2007;133:496–506.
4. K.M.Korenblat, E.Fabbrini, B.S.Mohammed, Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008;134:1369–1375.
5. A.L.Birkenfeld, G.I.Shulman. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 Diabetes. Hepatology 2014;59:713–723.
6. A.M.Zivkovic, J.B.German, A.J.Sanyal. Comparative review of diets for the metabolic syndrome:implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007;86:285-300.
7. B.Q.Starley, C.J.Calcagno, S.A.Harrison. Nonalcoholic fatty liver disease and hepatocellular carcinoma:a weighty connection. Hepatology 5:1820–1832.
8. R.K.Fox. When to consider liver transplant during the management of chronic liver disease. Med Clin North Am. 2014;98:153–168.
9. S.Hoppe, C.von Loeffelholz, J.F.Lock, Nonalcoholic steatohepatits and liver steatosis modify partial hepatectomy recovery. J Invest Surg. 2015;28:24–31.
10. X.Wang, J.Li, D.R.Riaz, et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis:a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:394–402.
11. J.Koskinas, I.P.Gomatos, D.G.Tiniakos, Liver histology in ICU patients dying from sepsis:a clinico-pathological study. World J Gastroenterol. 2008;14:1389–1393.
12. R.Vetelainen, A.van Vliet, D.J.Gouma, Steatosis as a risk factor in liver surgery. Ann Surg. 2007;245:20–30.
13. N.Stefan, H.U.Haring. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9:144–152.
14. K.Kantartzis, J.Machann, F.Schick, The impact of liver fat vs. visceral fat in determining categories of prediabetes. Diabetologia 2010;53:882–889.
15. Y.Yilmaz, O.Yonal, R.Kurt, Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease:relation with liver fibrosis. Ann Clin Biochem. 2010;47:549–553.
16. A.Kahraman, J.P.Sowa, M.Schlattjan, Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci (Lond) 2013;125:391–400.
17. E.M.Brunt, D.G.Tiniakos. Pathological features of NASH. Front Biosci. 2005;10:1475–1484.
18. G.Rossi. Diagnosis and classification of diabetes mellitus. Recenti Prog Med. 2010;101:274-276.
19. D.R.Matthews, J.P.Hosker, A.S.Rudenski, Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
20. J.G.Hattersley, M.Mohlig, M.Roden, Quantifying the improvement of surrogate indices of hepatic insulin resistance using complex measurement techniques. PLoS One 2012;7:e39029.
21. D.E.Kleiner, E.M.Brunt, M.Van Natta, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321.
22. F.Z.Aly, D.E.Kleiner. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol. 2011;18:294–300.
23. S.Docke, J.F.Lock, A.L.Birkenfeld, Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol. 2013;169:547–557.
24. P.Kulozik, A.Jones, F.Mattijssen, Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab. 2011;13:389–400.
25. B.Denecke, S.Graber, C.Schafer, Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 2003;376:135–145.
26. S.Mukhopadhyay, S.A.Mondal, M.Kumar, Proinflammatory and antiinflammatory attributes of fetuin-a:a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr Pract. 2014;20:1345–1351.
27. J.H.Ix, M.G.Shlipak, V.M.Brandenburg, Association between human fetuin-A and the metabolic syndrome:data from the Heart and Soul study. Circulation 2006;113:1760–1767.
28. H.Y.Chen, C.C.Lin, Y.L.Chiu, Serum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patients. PLoS One 2012;7:e38415.
29. H.Y.Ou, Y.C.Yang, H.T.Wu, Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab. 2012;97:4717–4723.
30. R.Rametta, M.Ruscica, P.Dongiovanni, Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance. Eur J Clin Invest. 2014;44:627–633.
31. A.Obuchi, H.Adachi, M.Enomoto, High plasma fetuin-A levels are associated with metabolic syndrome among males but not females in a Japanese general population. Diabetes Res Clin Pract. 2014;106:128–135.
32. L.Yin, W.J.Cai, X.Y.Chang, Association between fetuin-A levels with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus. Biomed Rep. 2014;2:839–842.
33. J.W.Haukeland, T.B.Dahl, A.Yndestad, Fetuin A in nonalcoholic fatty liver disease:in vivo and in vitro studies. Eur J Endocrinol. 2012;166:503–510.
34. X.Lin, H.D.Braymer, G.A.Bray, Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity. Life Sci. 1996;63:145–153.
35. H.Y.Ou, H.T.Wu, H.C.Hung, Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. Endocrinology 2012;153:2974–2984.
36. S.Dasgupta, S.Bhattacharya, A.Biswas, NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J. 2010;429:451–462.
37. M.Roden. Mechanisms of Disease:hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335–348.